European Journal of Cancer
Volume 39, Issue 7 , Pages 881-890, May 2003

Quantification of angiogenesis as a prognostic marker in human carcinomas:

a critical evaluation of histopathological methods for estimation of vascular density

Danish Cancer Society, Department of Experimental Clinical Oncology, Aarhus University Hospital, Nørrebrogade 44, bld. 5, DK-8000 Aarhus C, Denmark

Received 16 April 2002; received in revised form 30 August 2002; accepted 9 October 2002.

Abstract 

Chalkley counts have been suggested as the primary method for immunohistochemical evaluation of angiogenesis, however, most studies have used microvessel density (MVD). We present paired Chalkley and MVD estimates in carcinomas of the prostate, breast, bladder and lung. The clinical data has previously been reported. In prostate carcinomas, high MVD indicated poor prognosis, whereas high Chalkley counts in breast carcinoma were associated with a poor prognosis. In bladder carcinoma, high estimates using both methods showed good prognosis and were associated with a high degree of inflammation. Neither of the counts revealed prognostic value in lung carcinomas, where the vascular pattern indicated that this cancer was non-angiogenic. We highlight methodological problems with both counting methods. Since angiogenic processes in lung and bladder cancers may be different from those occuring in prostate cancer, we suggest that future analyses also focus on measuring angiogenic factors to obtain more information on the biology of angiogenesis.

Keywords:  Angiogenesis, Chalkley, Microvessel density, Breast, Bladder, Prostate, Non-small cell lung carcinoma

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0959-8049(02)00663-9

doi:10.1016/S0959-8049(02)00663-9

European Journal of Cancer
Volume 39, Issue 7 , Pages 881-890, May 2003